Stockreport

Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

Advaxis, Inc.  (ADXS) 
Last advaxis, inc. earnings: 9/9 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.advaxis.com
PDF First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with K [Read more]